Site icon OncologyTube

Gemtuzumab ozogamicin for AML: challenges and reapproval

Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the antibody-drug conjugate gemtuzumab ozogamicin for acute myeloid leukemia (AML). Prof. Burnett covers the history of this drug, the challenges faced and the future of this therapy. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Exit mobile version